Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: EAH
Latest Price: 218.50p  (0,00%)
52-week High: 234.00p
52-week Low: 186.50p
Market Cap: 120.44M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Eco Animal Health Group Plc
www.ecoanimalhealthgroupplc.com

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Pdf

ECO Animal Health shares rise after Canadian regulatory approval

28th Nov 2011, 7:27 am by Jamie Ashcroft Aivlosin is a water soluble product which comes in the form of granules that dissolve readily in water. This enables a simple solution for the accurate and simultaneous treatment of large numbers of animals.

Shares in veterinary pharmaceutical company ECO Animal Health (LON:EAH) gained around 5 per cent today after it received a key approval for its Aivlosin product in Canada.

It revealed today that the Veterinary Drugs Directorate (VDD) of Health Canada has granted a marketing authorisation for Aivlosin 625 mg/g water soluble granules for pigs.

This formulation will be marketed for the treatment of an enteric disease of pigs, ECO said.

The firm said that this is the group’s first approval in North America and it marks a very important step in its development of Aivlosin as a global veterinary product. 

“Following years of investment in regulatory applications in North America via our Princeton, New Jersey office, we are delighted to receive our first registration in this important continent,” said chairman and chief executive Peter Lawrence.

“Canada and the USA represent more than one third of the world market for our products and this breakthrough will benefit our future profitable growth. 

He added: “We expect our first approval from the FDA in the USA in the near future. 

“This approval, coupled with our existing approvals in other countries, will in effect give us the rights to sell Aivlosin around the world. This will be another important step in making ECO one of the most important global animal health companies”.

According to ECO, Canada is currently enjoying an increase in its pig population following consolidation among producers, which bodes well for company. ECO has established its own company in Canada to help ensure a successful launch.

Aivlosin is a water soluble product which comes in the form of granules that dissolve readily in water. This enables a simple solution for the accurate and simultaneous treatment of large numbers of animals.

The company said that the new Canadian approval means that ECO can extend its marketing reach for Aivlosin.

ECO also noted that it will announce its interim results on Monday 12 December.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.